FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2052503411> ?p ?o ?g. }

• W2052503411 endingPage "700" @default.
• W2052503411 startingPage "691" @default.
• W2052503411 abstract "Background Metformin is the recommended first-line pharmacotherapy for patients with type 2 diabetes. There is no consensus on the optimum second-line pharmacotherapy. We compared the efficacy and safety of the sodium glucose cotransporter 2 inhibitor empagliflozin and the sulfonylurea glimepiride as add-on to metformin in patients with type 2 diabetes. Methods In this double-blind phase 3 trial, patients (aged ≥18 years) with type 2 diabetes and HbA1c concentrations of 7–10%, despite metformin treatment and diet and exercise counselling, were randomly assigned in a 1:1 ratio with a computer-generated random sequence, stratified by HbA1c, estimated glomerular filtration rate (eGFR), and region, to empagliflozin (25 mg once daily, orally) or glimepiride (1–4 mg once daily, orally) as add-on to metformin for 104 weeks. Patients and investigators were masked to treatment assignment. The primary endpoint was change from baseline in HbA1c levels at weeks 52 and 104. Differences in the primary endpoint were first tested for non-inferiority (based on a margin of 0·3%). If non-inferiority was shown, differences in the primary endpoint at week 104 were then tested for superiority. Analysis was done on the full-analysis set—ie, patients who were treated with at least one dose of study drug and had a baseline HbA1c value. This study is registered with ClinicalTrials.gov, number NCT01167881. A 104-week extension is ongoing. Findings Between August, 2010, and June, 2011, 1549 patients were randomly assigned to receive empagliflozin (n=769) or glimepiride (n=780); four patients in the empagliflozin group did not receive the assigned treatment. Empagliflozin was non-inferior to glimepiride at both timepoints. At week 104, adjusted mean difference in change from baseline in HbA1c with empagliflozin versus glimepiride was −0·11% (95% CI −0·19 to −0·02; p=0·0153 for superiority). Adverse events were reported in 661 (86%) patients treated with empagliflozin and 673 (86%) patients treated with glimepiride. Severe adverse events were reported in 72 (9%) patients in the empagliflozin group and 68 (9%) in the glimepiride group. Serious adverse events were reported in 119 (16%) patients in the empagliflozin group and 89 (11%) in the glimepiride group. Confirmed hypoglycaemic adverse events (plasma glucose ≤3·9 mmol/L or requiring assistance) at week 104 were reported in 19 (2%) patients treated with empagliflozin and 189 (24%) patients treated with glimepiride. Interpretation Empagliflozin might be an effective and a well tolerated second-line treatment option for patients with type 2 diabetes who have not achieved good glycaemic control on metformin. Funding Boehringer Ingelheim and Eli Lilly. Metformin is the recommended first-line pharmacotherapy for patients with type 2 diabetes. There is no consensus on the optimum second-line pharmacotherapy. We compared the efficacy and safety of the sodium glucose cotransporter 2 inhibitor empagliflozin and the sulfonylurea glimepiride as add-on to metformin in patients with type 2 diabetes. In this double-blind phase 3 trial, patients (aged ≥18 years) with type 2 diabetes and HbA1c concentrations of 7–10%, despite metformin treatment and diet and exercise counselling, were randomly assigned in a 1:1 ratio with a computer-generated random sequence, stratified by HbA1c, estimated glomerular filtration rate (eGFR), and region, to empagliflozin (25 mg once daily, orally) or glimepiride (1–4 mg once daily, orally) as add-on to metformin for 104 weeks. Patients and investigators were masked to treatment assignment. The primary endpoint was change from baseline in HbA1c levels at weeks 52 and 104. Differences in the primary endpoint were first tested for non-inferiority (based on a margin of 0·3%). If non-inferiority was shown, differences in the primary endpoint at week 104 were then tested for superiority. Analysis was done on the full-analysis set—ie, patients who were treated with at least one dose of study drug and had a baseline HbA1c value. This study is registered with ClinicalTrials.gov, number NCT01167881. A 104-week extension is ongoing. Between August, 2010, and June, 2011, 1549 patients were randomly assigned to receive empagliflozin (n=769) or glimepiride (n=780); four patients in the empagliflozin group did not receive the assigned treatment. Empagliflozin was non-inferior to glimepiride at both timepoints. At week 104, adjusted mean difference in change from baseline in HbA1c with empagliflozin versus glimepiride was −0·11% (95% CI −0·19 to −0·02; p=0·0153 for superiority). Adverse events were reported in 661 (86%) patients treated with empagliflozin and 673 (86%) patients treated with glimepiride. Severe adverse events were reported in 72 (9%) patients in the empagliflozin group and 68 (9%) in the glimepiride group. Serious adverse events were reported in 119 (16%) patients in the empagliflozin group and 89 (11%) in the glimepiride group. Confirmed hypoglycaemic adverse events (plasma glucose ≤3·9 mmol/L or requiring assistance) at week 104 were reported in 19 (2%) patients treated with empagliflozin and 189 (24%) patients treated with glimepiride. Empagliflozin might be an effective and a well tolerated second-line treatment option for patients with type 2 diabetes who have not achieved good glycaemic control on metformin." @default.
• W2052503411 created "2016-06-24" @default.
• W2052503411 creator A5006125844 @default.
• W2052503411 creator A5012223927 @default.
• W2052503411 creator A5042381457 @default.
• W2052503411 creator A5043462775 @default.
• W2052503411 creator A5056571140 @default.
• W2052503411 creator A5085739516 @default.
• W2052503411 date "2014-09-01" @default.
• W2052503411 modified "2023-10-16" @default.
• W2052503411 title "Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial" @default.
• W2052503411 cites W1978270587 @default.
• W2052503411 cites W1991162814 @default.
• W2052503411 cites W2008443217 @default.
• W2052503411 cites W2029477388 @default.
• W2052503411 cites W2051243940 @default.
• W2052503411 cites W2077109510 @default.
• W2052503411 cites W2077636750 @default.
• W2052503411 cites W2086588588 @default.
• W2052503411 cites W2097519488 @default.
• W2052503411 cites W2101374656 @default.
• W2052503411 cites W2109728760 @default.
• W2052503411 cites W2111876001 @default.
• W2052503411 cites W2118613762 @default.
• W2052503411 cites W2119981294 @default.
• W2052503411 cites W2120600312 @default.
• W2052503411 cites W2130570549 @default.
• W2052503411 cites W2134855422 @default.
• W2052503411 cites W2136226749 @default.
• W2052503411 cites W2137069992 @default.
• W2052503411 cites W2137107263 @default.
• W2052503411 cites W2146901298 @default.
• W2052503411 cites W2147999853 @default.
• W2052503411 cites W2159883745 @default.
• W2052503411 cites W2165956693 @default.
• W2052503411 cites W2171183320 @default.
• W2052503411 cites W2171471305 @default.
• W2052503411 cites W92458862 @default.
• W2052503411 doi "https://doi.org/10.1016/s2213-8587(14)70120-2" @default.
• W2052503411 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24948511" @default.
• W2052503411 hasPublicationYear "2014" @default.
• W2052503411 type Work @default.
• W2052503411 sameAs 2052503411 @default.
• W2052503411 citedByCount "283" @default.
• W2052503411 countsByYear W20525034112014 @default.
• W2052503411 countsByYear W20525034112015 @default.
• W2052503411 countsByYear W20525034112016 @default.
• W2052503411 countsByYear W20525034112017 @default.
• W2052503411 countsByYear W20525034112018 @default.
• W2052503411 countsByYear W20525034112019 @default.
• W2052503411 countsByYear W20525034112020 @default.
• W2052503411 countsByYear W20525034112021 @default.
• W2052503411 countsByYear W20525034112022 @default.
• W2052503411 countsByYear W20525034112023 @default.
• W2052503411 crossrefType "journal-article" @default.
• W2052503411 hasAuthorship W2052503411A5006125844 @default.
• W2052503411 hasAuthorship W2052503411A5012223927 @default.
• W2052503411 hasAuthorship W2052503411A5042381457 @default.
• W2052503411 hasAuthorship W2052503411A5043462775 @default.
• W2052503411 hasAuthorship W2052503411A5056571140 @default.
• W2052503411 hasAuthorship W2052503411A5085739516 @default.
• W2052503411 hasConcept C126322002 @default.
• W2052503411 hasConcept C134018914 @default.
• W2052503411 hasConcept C168563851 @default.
• W2052503411 hasConcept C203092338 @default.
• W2052503411 hasConcept C2775887513 @default.
• W2052503411 hasConcept C2776307423 @default.
• W2052503411 hasConcept C2777180221 @default.
• W2052503411 hasConcept C2778854520 @default.
• W2052503411 hasConcept C2779306644 @default.
• W2052503411 hasConcept C2780323712 @default.
• W2052503411 hasConcept C555293320 @default.
• W2052503411 hasConcept C71924100 @default.
• W2052503411 hasConceptScore W2052503411C126322002 @default.
• W2052503411 hasConceptScore W2052503411C134018914 @default.
• W2052503411 hasConceptScore W2052503411C168563851 @default.
• W2052503411 hasConceptScore W2052503411C203092338 @default.
• W2052503411 hasConceptScore W2052503411C2775887513 @default.
• W2052503411 hasConceptScore W2052503411C2776307423 @default.
• W2052503411 hasConceptScore W2052503411C2777180221 @default.
• W2052503411 hasConceptScore W2052503411C2778854520 @default.
• W2052503411 hasConceptScore W2052503411C2779306644 @default.
• W2052503411 hasConceptScore W2052503411C2780323712 @default.
• W2052503411 hasConceptScore W2052503411C555293320 @default.
• W2052503411 hasConceptScore W2052503411C71924100 @default.
• W2052503411 hasIssue "9" @default.
• W2052503411 hasLocation W20525034111 @default.
• W2052503411 hasLocation W20525034112 @default.
• W2052503411 hasOpenAccess W2052503411 @default.
• W2052503411 hasPrimaryLocation W20525034111 @default.
• W2052503411 hasRelatedWork W1831536039 @default.
• W2052503411 hasRelatedWork W1986052847 @default.
• W2052503411 hasRelatedWork W2033298063 @default.
• W2052503411 hasRelatedWork W2052503411 @default.
• W2052503411 hasRelatedWork W2326091077 @default.
• W2052503411 hasRelatedWork W2532067257 @default.
• W2052503411 hasRelatedWork W2809903778 @default.
• W2052503411 hasRelatedWork W2927285401 @default.

• next